[{"id":"1c46647b-3ee2-489b-b3d5-6f10948818ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT04447547","created_at":"2021-01-18T21:24:04.198Z","updated_at":"2024-07-02T16:36:40.582Z","phase":"","brief_title":"Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT04447547","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" CD19 • IFNG • IL6 • TNFA • IL10","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • IFNG • IL6 • TNFA • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • S1904 • Senl 1904B"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/30/2020","start_date":" 06/30/2020","primary_txt":" Primary completion: 08/30/2022","primary_completion_date":" 08/30/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2020-09-29"},{"id":"0edb6ef9-4150-443b-8df9-568ab5c5b766","acronym":"","url":"https://clinicaltrials.gov/study/NCT04546893","created_at":"2021-01-18T21:45:01.127Z","updated_at":"2024-07-02T16:36:41.067Z","phase":"","brief_title":"Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia","source_id_and_acronym":"NCT04546893","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" IFNG • IL6 • TNFA • IL10","pipe":" | ","alterations":" CD19 positive","tags":["IFNG • IL6 • TNFA • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • S1904 • Senl 1904B"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-09-14"}]